『Medmastery's Cardiology Digest』のカバーアート

Medmastery's Cardiology Digest

Medmastery's Cardiology Digest

著者： Medmastery
無料で聴く

このコンテンツについて

 In 15 minutes or less, keep up to date on the latest studies and advancements in cardiology with the award-winning, leading clinical skills training platform, Medmastery! We’re recommended by the British Medical Association, and hundreds of thousands of clinicians around the world trust us to simplify complex information. We make it bite-sized, and easy to fit into your daily routine! In the complex and rapidly evolving field of cardiology, with new treatments and technologies emerging all the time, it can be tough to keep up with all the papers published on a daily basis. That's where our Cardiology Digest comes in. Our cardiology experts select the most important papers. Then we break them down into easy-to-understand, digestible nuggets that help you stay informed and empowered to make the right decisions for your patients. From heart disease to arrhythmias, we cover a range of topics—including cutting-edge diagnostic tools and treatment options—that are relevant to the field. So, if you're looking for a simple, accessible way to stay up to date with the latest trends and advancements in cardiology and medicine, tune in to Medmastery's Cardiology Digest! Visit us at www.medmastery.com!2024 博物学 科学 自然・生態学 衛生・健康的な生活 身体的病い・疾患
エピソード
  • #25: Influenza and myocardial infarction, fasting protocols for cath lab procedures, anticoagulation therapy and transcatheter aortic-valve replacement

    #25: Influenza and myocardial infarction, fasting protocols for cath lab procedures, anticoagulation therapy and transcatheter aortic-valve replacement
    2024/10/08
    In today’s episode of Cardiology Digest, we look at three recent research papers that can impact your clinical practice. They’re from NEJM Evidence, the European Heart Journal, and The New England Journal of Medicine. STUDY #1: Today’s journey begins with a study examining the interplay between influenza and myocardial infarctions. Could the flu shot be more than just a seasonal precaution? de Boer, AR, Riezebos-Brilman, A, van Hout, D, et al. 2024. Influenza infection and acute myocardial infarction. NEJM Evid. 7:EVIDoa2300361. (https://doi.org/10.1056/EVIDoa2300361) STUDY #2: Next, we wade into a cath lab debate over fasting protocols. Join us to explore research that flips traditional pre-procedure fasting requirements on their head. Are we on the brink of a new era? Ferreira, D, Hardy, J, Meere, W, et al. 2024. Fasting vs no fasting prior to catheterisation laboratory procedures: The SCOFF trial. Eur Heart J. Published online. (https://doi.org/10.1093/eurheartj/ehae573) STUDY #3: Finally, we dig into the complexities of anticoagulation in transcatheter aortic-valve replacement patients. This study sheds light on the choice between interrupting or continuing anticoagulation, and has implications for everyday practice. van Ginkel, DJ, Bor, WL, Aarts, HM, et al. 2024. Continuation versus interruption of oral anticoagulation during TAVI. N Engl J Med. Published online. (https://doi.org/10.1056/NEJMoa2407794) Tune in for a captivating discussion that promises to enrich your clinical acumen! Learn more with Medmastery's courses: Coronary Angiography Essentials (3 CME) Coronary Angiography Essentials Workshop (1 CME) ICD Essentials (4 CME) ICD Essentials Workshop (1 CME) Pacemaker Essentials (5 CME) Pacemaker Essentials Workshop (1 CME) Percutaneous Coronary Intervention Essentials (6 CME) Percutaneous Coronary Intervention Essentials Workshop (6 CME) Get a Basic or Pro account, or, get a Trial account. Show notes: Visit us at https://www.medmastery.com/podcasts/cardiology-podcast.
    続きを読む 一部表示
    11 分
  • #24: Patient selection and antiplatelet therapy for percutaneous coronary intervention (PCI), the best anticoagulants for patients with atrial fibrillation

    #24: Patient selection and antiplatelet therapy for percutaneous coronary intervention (PCI), the best anticoagulants for patients with atrial fibrillation
    2024/09/24

    In this episode of Medmastery’s Cardiology Digest, we dive into three groundbreaking studies that are set to reshape our understanding and approach to cardiology.

    STUDY #1: First, we discuss a landmark piece of research that sheds new light on the benefits of percutaneous coronary intervention for patients with significant coronary artery disease who need a transcatheter aortic valve replacement. This study addresses important questions about patient selection for this intervention.

    Lønborg, J, Jabbari, R, Sabbah, M, et al. 2024. PCI in patients undergoing transcatheter aortic-valve implantation. N Engl J Med. Published online. (https://doi.org/10.1056/NEJMoa2401513)

    STUDY #2: Next, we examine an insightful meta-analysis that evaluates patient-level data to inform the future of dual antiplatelet therapy after percutaneous coronary intervention. Discover the factors influencing the transition to ticagrelor monotherapy post-PCI and why this could change current guideline recommendations.

    Valgimigli, M, Hong, S, Gragnano, F, et al. 2024. De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: A systematic review and individual patient-level meta-analysis of randomized trials. Lancet. 10456: 937–948. (https://doi.org/10.1016/S0140-6736(24)01616-7)

    STUDY #3: Lastly, we take a closer look at the EPIC-CAD study, which aligns with previous findings from the AFIRE trial. Learn why anticoagulant monotherapy is now being considered for the majority of patients with atrial fibrillation who require anticoagulation and have stable coronary artery disease, and what this means for your clinical practice.

    Cho, MS, Kang, D-Y, Ahn, J-M, et al. 2024. Edoxaban antithrombotic therapy for atrial fibrillation and stable coronary artery disease. N Engl J Med. Published online. (https://doi.org/10.1056/NEJMoa2407362)

    Tune in to this episode for an engaging in-depth discussion of these studies and stay ahead in the ever-evolving field of cardiology!

    Learn more with Medmastery's courses:

    Percutaneous Coronary Intervention Essentials (6 CME)

    Percutaneous Coronary Intervention Essentials Workshop (6 CME)

    Get a Basic or Pro account, or, get a Trial account.

    Show notes:

    Visit us at https://www.medmastery.com/podcasts/cardiology-podcast.
    続きを読む 一部表示
    11 分
  • #23: Edoxaban dosage and atrial fibrillation, invasive vs. noninvasive treatment of NSTEMI, chelation therapy for coronary artery disease

    #23: Edoxaban dosage and atrial fibrillation, invasive vs. noninvasive treatment of NSTEMI, chelation therapy for coronary artery disease
    2024/09/10

    Stay ahead with the newest cardiology research findings that could change your clinical practice!

    STUDY #1: First up, we explore new data on edoxaban dosage for older patients with atrial fibrillation. If we could give older patients a lower dose of edoxaban to reduce the risk of bleeding, will they still benefit from a lower risk for stroke?

    Zimerman, A, Braunwald, E, Steffel, J, et al. 2024. Dose reduction of edoxaban in patients 80 years and older with atrial fibrillation: Post hoc analysis of the ENGAGE AF-TIMI 48 randomized clinical trial. JAMA Cardiol. Published online. (https://doi.org/10.1001/jamacardio.2024.1793)

    STUDY #2: Next, we delve into the nuanced world of invasive versus noninvasive treatment of non-ST-segment elevation myocardial infarction (NSTEMI). You’ll find out if mortality rates go up when we use a less invasive approach.

    Kunadian, V, Mossop, H, Shields, C, et al. 2024. Invasive treatment strategy for older patients with myocardial infarction. N Engl J Med. Published online. (https://doi.org/10.1056/NEJMoa2407791)

    STUDY #3: Lastly, we break down the latest findings on chelation therapy in patients with stable coronary artery disease and diabetes. Tune it to see whether the latest data challenges your perspective on the efficacy of EDTA in reducing cardiovascular risks.

    Lamas, GA, Anstrom, KJ, Navas-Acien, A, et al. 2024. Edetate disodium-based chelation for patients with a previous myocardial infarction and diabetes: TACT2 randomized clinical trial. JAMA. Published online. (https://doi.org/10.1001/jama.2024.11463)

    Join us to uncover these critical insights, discussions, and more. Let's turn data into actionable wisdom and elevate your cardiology practice.

    Learn more with Medmastery's courses:

    ECG Mastery Program (34 CME)

    Get a Basic or Pro account, or, get a Trial account.

    Show notes:

    Visit us at https://www.medmastery.com/podcasts/cardiology-podcast.
    続きを読む 一部表示
    11 分
まだレビューはありません